Skip to main content
Journal cover image

Metabolomic and inflammatory signatures of symptom dimensions in major depression.

Publication ,  Journal Article
Brydges, CR; Bhattacharyya, S; Dehkordi, SM; Milaneschi, Y; Penninx, B; Jansen, R; Kristal, BS; Han, X; Arnold, M; Kastenmüller, G; Bekhbat, M ...
Published in: Brain Behav Immun
May 2022

BACKGROUND: Major depressive disorder (MDD) is a highly heterogenous disease, both in terms of clinical profiles and pathobiological alterations. Recently, immunometabolic dysregulations were shown to be correlated with atypical, energy-related symptoms but less so with the Melancholic or Anxious distress symptom dimensions of depression in The Netherlands Study of Depression and Anxiety (NESDA) study. In this study, we aimed to replicate these immunometabolic associations and to characterize the metabolomic correlates of each of the three MDD dimensions. METHODS: Using three clinical rating scales, Melancholic, and Anxious distress, and Immunometabolic (IMD) dimensions were characterized in 158 patients who participated in the Predictors of Remission to Individual and Combined Treatments (PReDICT) study and from whom plasma and serum samples were available. The NESDA-defined inflammatory index, a composite measure of interleukin-6 and C-reactive protein, was measured from pre-treatment plasma samples and a metabolomic profile was defined using serum samples analyzed on three metabolomics platforms targeting fatty acids and complex lipids, amino acids, acylcarnitines, and gut microbiome-derived metabolites among other metabolites of central metabolism. RESULTS: The IMD clinical dimension and the inflammatory index were positively correlated (r = 0.19, p = 0.019) after controlling for age, sex, and body mass index, whereas the Melancholic and Anxious distress dimensions were not, replicating the previous NESDA findings. The three symptom dimensions had distinct metabolomic signatures using both univariate and set enrichment statistics. IMD severity correlated mainly with gut-derived metabolites and a few acylcarnitines and long chain saturated free fatty acids. Melancholia severity was significantly correlated with several phosphatidylcholines, primarily the ether-linked variety, lysophosphatidylcholines, as well as several amino acids. Anxious distress severity correlated with several medium and long chain free fatty acids, both saturated and polyunsaturated ones, sphingomyelins, as well as several amino acids and bile acids. CONCLUSION: The IMD dimension of depression appears reliably associated with markers of inflammation. Metabolomics provides powerful tools to inform about depression heterogeneity and molecular mechanisms related to clinical dimensions in MDD, which include a link to gut microbiome and lipids implicated in membrane structure and function.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Brain Behav Immun

DOI

EISSN

1090-2139

Publication Date

May 2022

Volume

102

Start / End Page

42 / 52

Location

Netherlands

Related Subject Headings

  • Neurology & Neurosurgery
  • Metabolomics
  • Humans
  • Fatty Acids, Nonesterified
  • Depressive Disorder, Major
  • Depression
  • Amino Acids
  • 5202 Biological psychology
  • 3209 Neurosciences
  • 3204 Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Brydges, C. R., Bhattacharyya, S., Dehkordi, S. M., Milaneschi, Y., Penninx, B., Jansen, R., … Mood Disorders Precision Medicine Consortium, . (2022). Metabolomic and inflammatory signatures of symptom dimensions in major depression. Brain Behav Immun, 102, 42–52. https://doi.org/10.1016/j.bbi.2022.02.003
Brydges, Christopher R., Sudeepa Bhattacharyya, Siamak Mahmoudian Dehkordi, Yuri Milaneschi, Brenda Penninx, Rick Jansen, Bruce S. Kristal, et al. “Metabolomic and inflammatory signatures of symptom dimensions in major depression.Brain Behav Immun 102 (May 2022): 42–52. https://doi.org/10.1016/j.bbi.2022.02.003.
Brydges CR, Bhattacharyya S, Dehkordi SM, Milaneschi Y, Penninx B, Jansen R, et al. Metabolomic and inflammatory signatures of symptom dimensions in major depression. Brain Behav Immun. 2022 May;102:42–52.
Brydges, Christopher R., et al. “Metabolomic and inflammatory signatures of symptom dimensions in major depression.Brain Behav Immun, vol. 102, May 2022, pp. 42–52. Pubmed, doi:10.1016/j.bbi.2022.02.003.
Brydges CR, Bhattacharyya S, Dehkordi SM, Milaneschi Y, Penninx B, Jansen R, Kristal BS, Han X, Arnold M, Kastenmüller G, Bekhbat M, Mayberg HS, Craighead WE, Rush AJ, Fiehn O, Dunlop BW, Kaddurah-Daouk R, Mood Disorders Precision Medicine Consortium. Metabolomic and inflammatory signatures of symptom dimensions in major depression. Brain Behav Immun. 2022 May;102:42–52.
Journal cover image

Published In

Brain Behav Immun

DOI

EISSN

1090-2139

Publication Date

May 2022

Volume

102

Start / End Page

42 / 52

Location

Netherlands

Related Subject Headings

  • Neurology & Neurosurgery
  • Metabolomics
  • Humans
  • Fatty Acids, Nonesterified
  • Depressive Disorder, Major
  • Depression
  • Amino Acids
  • 5202 Biological psychology
  • 3209 Neurosciences
  • 3204 Immunology